JP2020512388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512388A5 JP2020512388A5 JP2019554037A JP2019554037A JP2020512388A5 JP 2020512388 A5 JP2020512388 A5 JP 2020512388A5 JP 2019554037 A JP2019554037 A JP 2019554037A JP 2019554037 A JP2019554037 A JP 2019554037A JP 2020512388 A5 JP2020512388 A5 JP 2020512388A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- recombinant antibody
- sequence described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022105552A JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382617.5 | 2016-12-19 | ||
| EP16382617 | 2016-12-19 | ||
| US201762467017P | 2017-03-03 | 2017-03-03 | |
| US62/467,017 | 2017-03-03 | ||
| EP17382683 | 2017-10-13 | ||
| EP17382683.5 | 2017-10-13 | ||
| PCT/IB2017/001677 WO2018115960A1 (en) | 2016-12-19 | 2017-12-18 | Antibodies against lif and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105552A Division JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512388A JP2020512388A (ja) | 2020-04-23 |
| JP2020512388A5 true JP2020512388A5 (https=) | 2021-05-13 |
| JP7100056B2 JP7100056B2 (ja) | 2022-07-12 |
Family
ID=67138942
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554037A Active JP7100056B2 (ja) | 2016-12-19 | 2017-12-18 | Ｌｉｆに対する抗体及びその使用 |
| JP2022105552A Active JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A Pending JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022105552A Active JP7459173B2 (ja) | 2016-12-19 | 2022-06-30 | Ｌｉｆに対する抗体及びその使用 |
| JP2024044049A Pending JP2024075682A (ja) | 2016-12-19 | 2024-03-19 | Ｌｉｆに対する抗体及びその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11390670B2 (https=) |
| EP (2) | EP3555132B1 (https=) |
| JP (3) | JP7100056B2 (https=) |
| KR (3) | KR102716931B1 (https=) |
| CN (2) | CN111868086B (https=) |
| AU (1) | AU2017381585B2 (https=) |
| BR (1) | BR112019012691A2 (https=) |
| CA (1) | CA3047528A1 (https=) |
| CL (2) | CL2019001717A1 (https=) |
| DK (1) | DK3555132T3 (https=) |
| ES (1) | ES2971126T3 (https=) |
| FI (1) | FI3555132T3 (https=) |
| HR (1) | HRP20240195T8 (https=) |
| HU (1) | HUE065241T2 (https=) |
| IL (2) | IL294088B2 (https=) |
| LT (1) | LT3555132T (https=) |
| MX (2) | MX2019007376A (https=) |
| PL (1) | PL3555132T3 (https=) |
| RS (1) | RS65187B1 (https=) |
| SA (1) | SA519402119B1 (https=) |
| SI (1) | SI3555132T1 (https=) |
| SM (1) | SMT202400065T1 (https=) |
| ZA (1) | ZA201904533B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017381585B2 (en) * | 2016-12-19 | 2025-02-13 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Antibodies against LIF and uses thereof |
| WO2019197903A1 (en) * | 2018-04-12 | 2019-10-17 | Mosaic Biomedicals Slu | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
| EP4069736A1 (en) * | 2019-12-04 | 2022-10-12 | MedImmune Limited | Antibodies against lif and uses thereof |
| TWI841810B (zh) | 2020-01-24 | 2024-05-11 | 日商西斯美股份有限公司 | 提升抗體對抗原之親和性的方法及其用途 |
| JP7691668B2 (ja) | 2020-12-31 | 2025-06-12 | 諾納生物（蘇州）有限公司 | ヒトｌｉｆｒ抗原結合タンパク質、その製造方法及び応用 |
| AU2022273303A1 (en) * | 2021-05-14 | 2023-11-02 | Genentech, Inc. | Agonists of trem2 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| WO1993023665A1 (en) | 1992-05-15 | 1993-11-25 | Re/Map Incorporated | Electromagnetic shielding for a liquid conditioning device |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| DE69635630T2 (de) | 1995-04-24 | 2006-08-10 | Genentech, Inc., South San Francisco | Verwendung eines Leukämie-hemmenden Faktor Antagonisten |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| AU2003218456A1 (en) | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1612558A1 (en) | 2004-06-30 | 2006-01-04 | Academisch Ziekenhuis Leiden | Method for detecting gluten |
| EP1877075A4 (en) | 2005-04-25 | 2008-07-30 | Pfizer | ANTIBODY TO MYOSTATIN |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| JP2010505876A (ja) | 2006-10-04 | 2010-02-25 | ザ スクリプス リサーチ インスティテュート | ヒトメタニューモウイルスを中和するヒト抗体 |
| CN101440128A (zh) | 2007-11-21 | 2009-05-27 | 中国人民解放军第二军医大学 | 人脑胶质瘤中差异表达的蛋白及其用途 |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| ES2363358B1 (es) | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| WO2011057144A2 (en) | 2009-11-06 | 2011-05-12 | La Jolla Institute For Allergy And Immunology | Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| US20140314741A1 (en) | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
| JP6488520B2 (ja) | 2013-08-20 | 2019-03-27 | 国立研究開発法人科学技術振興機構 | ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法 |
| US20150056195A1 (en) | 2013-08-23 | 2015-02-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compositions and methods for inihibiting tumorigenicity of senescent cancer cells induced by chemotherapy |
| US20160237158A1 (en) | 2013-09-23 | 2016-08-18 | Institut National De La Santé Et Da La Recherche Médicale (Inserm) | Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis |
| US10808026B2 (en) | 2013-10-09 | 2020-10-20 | Research Development Foundation | Monoclonal Olfml-3 antibodies and uses thereof |
| TWI486172B (zh) | 2013-11-08 | 2015-06-01 | 長庚大學 | 鼻咽癌治療的醫藥 |
| ES2866935T3 (es) | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| WO2016040657A1 (en) | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| AU2017381585B2 (en) * | 2016-12-19 | 2025-02-13 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Antibodies against LIF and uses thereof |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| WO2019197903A1 (en) * | 2018-04-12 | 2019-10-17 | Mosaic Biomedicals Slu | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
| CN112703202A (zh) * | 2018-06-18 | 2021-04-23 | 免疫医疗有限公司 | 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法 |
-
2017
- 2017-12-18 AU AU2017381585A patent/AU2017381585B2/en active Active
- 2017-12-18 FI FIEP17840489.3T patent/FI3555132T3/fi active
- 2017-12-18 EP EP17840489.3A patent/EP3555132B1/en active Active
- 2017-12-18 CN CN201780086859.0A patent/CN111868086B/zh active Active
- 2017-12-18 ES ES17840489T patent/ES2971126T3/es active Active
- 2017-12-18 HU HUE17840489A patent/HUE065241T2/hu unknown
- 2017-12-18 KR KR1020237027761A patent/KR102716931B1/ko active Active
- 2017-12-18 EP EP23209620.6A patent/EP4321219A3/en active Pending
- 2017-12-18 JP JP2019554037A patent/JP7100056B2/ja active Active
- 2017-12-18 HR HRP20240195TT patent/HRP20240195T8/hr unknown
- 2017-12-18 CA CA3047528A patent/CA3047528A1/en active Pending
- 2017-12-18 BR BR112019012691-0A patent/BR112019012691A2/pt unknown
- 2017-12-18 SM SM20240065T patent/SMT202400065T1/it unknown
- 2017-12-18 RS RS20240203A patent/RS65187B1/sr unknown
- 2017-12-18 DK DK17840489.3T patent/DK3555132T3/da active
- 2017-12-18 US US16/470,896 patent/US11390670B2/en active Active
- 2017-12-18 LT LTEPPCT/IB2017/001677T patent/LT3555132T/lt unknown
- 2017-12-18 PL PL17840489.3T patent/PL3555132T3/pl unknown
- 2017-12-18 IL IL294088A patent/IL294088B2/en unknown
- 2017-12-18 KR KR1020247033540A patent/KR102784394B1/ko active Active
- 2017-12-18 SI SI201731487T patent/SI3555132T1/sl unknown
- 2017-12-18 CN CN202410972902.5A patent/CN118652335A/zh active Pending
- 2017-12-18 IL IL267450A patent/IL267450B/en unknown
- 2017-12-18 KR KR1020197021098A patent/KR102599557B1/ko active Active
- 2017-12-18 MX MX2019007376A patent/MX2019007376A/es unknown
-
2019
- 2019-06-17 SA SA519402119A patent/SA519402119B1/ar unknown
- 2019-06-19 CL CL2019001717A patent/CL2019001717A1/es unknown
- 2019-06-19 MX MX2024003178A patent/MX2024003178A/es unknown
- 2019-07-10 ZA ZA2019/04533A patent/ZA201904533B/en unknown
-
2021
- 2021-04-16 CL CL2021000950A patent/CL2021000950A1/es unknown
-
2022
- 2022-06-23 US US17/808,319 patent/US20230042095A1/en not_active Abandoned
- 2022-06-30 JP JP2022105552A patent/JP7459173B2/ja active Active
-
2024
- 2024-03-19 JP JP2024044049A patent/JP2024075682A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP7036909B2 (ja) | 抗ｃｄ３８抗体および使用方法 | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP2020512388A5 (https=) | ||
| JP2018501197A5 (https=) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP7649744B2 (ja) | Ｂｔｎ３ａ結合タンパク質及びその使用 | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| KR20170068458A (ko) | 항-ｎｋｇ2ａ 항체를 사용한 치료 요법 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| CA2957491A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| JP2025004078A (ja) | ４－１ｂｂ結合タンパク質及びその用途 | |
| JP2022505925A (ja) | 抗ｔｉｍ－３抗体 | |
| WO2019072869A1 (en) | PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF | |
| JP2026049003A (ja) | Ｔｉｇｉｔとｃｄ１１２ｒ遮断 | |
| AU2018214222C1 (en) | Inhibition of platelet aggregation using anti-human GPVI antibodies | |
| JP7059389B2 (ja) | 抗ｐｄ－１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| US20250313631A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
| JP7059388B2 (ja) | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| AU2019358442B2 (en) | Antibodies targeting CD137 and methods of use thereof | |
| CN117177994A (zh) | 包含新颖pd-1结合域之多特异性结合部分 | |
| HK40076446B (en) | 4-1bb binding protein and application thereof |